Traws Pharma, Inc.
TRAWHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeTraws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. Valued at $5.3M, TRAW is a micro-cap name in its sector. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Market Cap
$5.3M
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
-0.18
EPS (TTM)
$-1.71
EPS (Fwd)
$-1.88
ROE
-433.4%
ROA
-99.4%
Cash
$5.0M
Total Debt
$0
Free CF
-$13.3M
52W Change
-86.9%
Annual Financials
Cash vs Debt
Where TRAW stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TRAW finished 63.00% below its 150-day moving average ($1.00) and 69.42% below its 200-day moving average ($1.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TRAW overbought or oversold?
At the October 20, 2026 close, TRAW's RSI(14) was 6.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Traws Pharma, Inc. reports $5.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$13.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -433.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $226K to $2.8M.
Traws Pharma, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TRAW.